Bone Abstracts

Scope: Extended Forsteo Observational Study (ExFOS), a multinational, non-interventional, prospective, observational study aims to evaluate fracture outcomes, back pain (BP), compliance and health-related Quality of Life (QoL) in osteoporotic patients prescribed teriparatide (TPTD). We present treatment outcomes for patients (male or female) treated for up to 24 months in Greece.

Methods: Of the 440 patients enrolled in the study 416 (mean age 69.9±9.7 years) have performed at least one active treatment post-baseline visit. These were predominantly women (92.1%), at postmenopausal stage (99.7%). Self-reported parameters of health perception have been recorded throughout the study through validated questionnaires (EQ-5D). We report the observed percent and mean responses.

Results: Seventeen (4.1%) patients had an incident clinical fracture during follow-up. Adherence: 80% of subjects used the treatment through month 23; 45% continued use through month 24. BMD numerically increased in all sites. Indicatively, Lumbar BMD T-score (mean (S.D.)) increased from −3.39 (0.73) at baseline to −2.36 (0.63) at study end. BP history the last year before enrollment was reported by 88.9%. During treatment, all self-reported variables improved. Examples of BP frequency (% of patients with BP fairly often or almost daily) and BP severity (% with moderate-severe BP), EQ-5D Visual Analogue Scale (VAS) score and EQ-5D mobility (% reporting some or extreme problems) are depicted below.

Conclusions: Use of TPTD remains high almost throughout the follow-up. A decrease at month 24 may be due to prescribing (24 months/26 cartridges) particularities. Patients experience improvement in BP and QoL. Fracture rate was low. Results should be interpreted in the context of an observational study.